Indication
Midgut Neuroendocrine Tumor
2 clinical trials
3 products
Clinical trial
A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)Status: Recruiting, Estimated PCD: 2025-09-30
Product
AbemaciclibClinical trial
NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NETStatus: Recruiting, Estimated PCD: 2026-04-30
Product
EverolimusProduct
Lutetium Lu 177 Dotatate